BigHat Biosciences, Inc. — SEC Form D Filing

BigHat Biosciences, Inc. filed an SEC Form D on October 26, 2026, reporting $75.14M raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
October 26, 2026
Amount reported
$75.14M
Round stage
Series B+
Industry
Biotechnology
Website
https://www.bighatbio.com

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Designing antibody and protein therapeutics for challenging conditions like cancers and infections requires solving complex molecular design hurdles and overcoming a shortage of high-integrity biological data needed to train and improve computational models.

Solution

BigHat Biosciences develops the Milliner platform, an engine that couples automated wet-lab experimentation with computational AI models to synthesize, characterize, and optimize thousands of recombinant antibodies each week.

Why now

Advances in protein language models and automated cell-free protein synthesis now enable active-learning feedback loops that bridge computational design with rapid experimental validation.

Verdict

This cleared because BigHat proved high-throughput wet-lab generation could resolve the data starvation stalling AI drug discovery, not because computational protein design models are inherently proprietary. Investors bet that tight active-learning loops could reliably compress optimization cycles for complex multi-specific antibodies where empirical screening stalls. Upside remains bounded by pipeline economics: platforms that fail to rapidly translate automated design speed into internally owned clinical assets ultimately get priced as discounted services rather than sovereign biotech powerhouses.

Source: SEC EDGAR Form D filing